There has been substantial media attention and reaction from affected patients regarding metal-on-metal hip implants over the last decade or so. Of course, one of the most famous examples is the articular surface replacement, or ASR, implant which was manufactured by DePuy Orthopaedics, a subsidiary of Johnson & Johnson. Tens of thousands of the devices were implanted in patients before injuries, immobility, and even metal poisoning led to their recall in 2010.
It has been several years since Michigan-based medical device manufacturer Stryker issued a voluntary recall of their Rejuvenate and ABH II modular-neck stem metal hip replacements, according to the U.S. Food and Drug Administration. The recall was made after many patients complained that the hip replacement was defective, causing them more pain and suffering than before the implant was surgically inserted.
Sometimes a medical device meant to provide relief for patients suffering and expedite healing causes more pain than relief. One of these devices is known as a pain pump, most commonly used in patients recovering from shoulder surgery after a serious shoulder injury.
An international group of scientists recently condemned Metal-on-Metal hip replacement implants. A report issued by the European Commission’s Scientific Committee on Emerging Newly Identified Health Risks concluded that metal-on-metal (MoM) devices should be “avoided” due to their “high failure rate.” Researchers stated that MoMs should be used only on a case-by-case basis, in light of other, more effective available alternatives.
Metal-on-metal hips were first marketed as providing a greater range of motion and longer lasting use for patients. However, due to poor design and performance of certain artificial hips, failure rates have rapidly increased. Medical device manufacturers Stryker and DuPuy both created and promoted products that did not undergo proper testing. As a result, many have suffered.
Boston Scientific (BSX) recently announced that it received a subpoena on May 5 from the Department of Health and Human Services. The subpoena asked the company for information about the performance of its implanted defibrillators. Defibrillator devices are used to shock racing hearts back into a normal rhythm during cardiac emergencies, some of which may injure patients.
Official warnings have been handed out to several companies advertising autism therapies and cures. Five total treatments were flagged in the statement from the FDA, which was announced during Autism Awareness Month. While some of the therapies are noted as useful medical therapies, there have not been scientific studies that show a connection to autism improvement.
The FDA recently launched a comprehensive investigation into the “low T” testosterone therapy program. Early research indicates that men may face a higher risk of premature death, stroke, or heart attacks by undergoing this therapy.